Clopidogrel Bisulfate
Product Images NDC 50090-1300

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 50090-1300). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500901300)

Label for Clopidogrel Bisulfate 75 mg tablets from A-S Medication Solutions with NDC 50090-1300-0. The label states the product is a calcium tablet equivalent to 75 mg Clopidogrel Bisulfate, packaged with 30 tablets. Storage instructions are to keep between 68 to 77 degrees Fahrenheit.*

FDA Label Image

Spl-clopidogrel-chemical-structure (Spl Clopidogrel Chemical Structure)

Chemical structure of Clopidogrel Bisulfate, showing its bicyclic thiophene-piperidine core, ester functional group, chlorophenyl ring, and associated sulfate moiety.*

FDA Label Image

Spl-clopidogrel-fig-7 (Spl Clopidogrel Fig 7)

A line graph titled 'Fatal or Nonfatal Vascular Events in the CAPRIE Study' showing cumulative event rates (%) over 36 months of follow-up. It compares two lines representing aspirin and clopidogrel, with clopidogrel showing a lower cumulative event rate than aspirin. The graph includes a p-value of 0.045 indicating statistical significance.*

FDA Label Image

Spl-clopidogrel-fig-8 (Spl Clopidogrel Fig 8)

A forest plot figure showing hazard ratios with 95% confidence intervals for baseline subgroups in the CAPRIE study comparing Clopidogrel versus Aspirin. Subgroups include Stroke, MI, PAD, and Overall, with data points represented graphically around the hazard ratio scale from 0.6 to 1.3, indicating relative favorability toward Clopidogrel or Aspirin.*

FDA Label Image

Spl-clopidogrel-figure1 (Spl Clopidogrel Figure1)

Figure showing exposure to clopidogrel active metabolite after multiple 75 mg doses alone or with proton pump inhibitors (PPIs). The horizontal bars represent the effect on active metabolite AUC with mean and 90% confidence intervals for PPIs: dexlansoprazole 60 mg, lansoprazole 30 mg, pantoprazole 80 mg, and omeprazole 80 mg, with change relative to clopidogrel alone on the x-axis.*

FDA Label Image

Spl-clopidogrel-figure2 (Spl Clopidogrel Figure2)

A line graph depicting cardiovascular death, myocardial infarction, and stroke event rates over 12 months of follow-up. It compares cumulative event rates (%) for Clopidogrel plus aspirin and placebo plus aspirin groups, showing lower rates for Clopidogrel. The graph highlights statistical significance with P = 0.00009 and notes other standard therapies were used as appropriate.*

FDA Label Image

Spl-clopidogrel-figure3 (Spl Clopidogrel Figure3)

A forest plot showing hazard ratios for patient baseline characteristics and on-study concomitant medications/interventions comparing Clopidogrel Bisulfate versus placebo in the CURE Study. The chart includes subgroups by age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, previous stroke, heparin/LMWH, aspirin dosage, GPIIb/IIIa antagonist use, beta-blocker use, and ACE inhibitor use. Each subgroup lists sample sizes and event rates with confidence intervals and hazard ratios depicted visually.*

FDA Label Image

Spl-clopidogrel-figure4 (Spl Clopidogrel Figure4)

A cumulative event rate graph showing the percentage of deaths before first discharge in the COMMIT study over 28 days since randomization. The graph compares placebo and clopidogrel groups, indicating 8.1% death rate for placebo and 7.5% for clopidogrel, with a 7% proportional risk reduction noted (p=0.03). All treated patients received aspirin.*

FDA Label Image

Spl-clopidogrel-figure5 (Spl Clopidogrel Figure5)

A cumulative event rate curve illustrating the combined endpoint of re-infarction, stroke, or death over 28 days in patients treated in the COMMIT study. The y-axis represents the percentage with death, reinfarction, or stroke before first discharge, and the x-axis shows days since randomization. Two lines compare placebo (10.1% event rate) and Clopidogrel (9.2% event rate), noting a 9% proportional risk reduction with Clopidogrel (p=0.002). All patients received aspirin.*

FDA Label Image

Spl-clopidogrel-figure6 (Spl Clopidogrel Figure6)

A forest plot figure showing the effects of adding Clopidogrel to aspirin on the combined primary endpoint across various subgroups in the COMMIT study. The chart compares odds ratios with 99% confidence intervals for subgroups by gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use, indicating whether the results favor Clopidogrel or placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.